New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
09. September 2024 16:16 ET
|
Treos Bio Corp.
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for...
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
03. Juni 2024 07:00 ET
|
Treos Bio Corp.
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
08. Mai 2024 07:45 ET
|
Treos Bio Corp.
LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said...
Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine
15. Juni 2020 07:15 ET
|
Treos Bio Corp.
LONDON, June 15, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing targeted peptide cancer immunotherapies, today said that it has developed and successfully...
Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation
29. Mai 2020 12:17 ET
|
Treos Bio Corp.
LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing precision peptide cancer immunotherapies, today presented positive final data from a Phase...
Treos Bio Presents Positive Data on Its Off-the-Shelf Shared Antigen-Based Cancer Vaccine Against Microsatellite-stable metastatic colorectal cancer and Personalized Vaccines Against Three Metastatic cancers
07. November 2019 07:00 ET
|
Treos Bio Corp.
LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Treos Bio has developed a unique approach to create cancer vaccines by focusing not just on the vaccine targets but also on delivering antigen targets to...
Treos Bio Reports Updated Positive Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer
26. September 2019 05:15 ET
|
Treos Bio Corp.
LONDON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Treos Bio Limited, which is developing personal cancer vaccines combined with companion diagnostic devices, reported updated positive results on the second...
Treos Bio Announces Positive Interim Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer
28. Mai 2019 08:15 ET
|
Treos Bio Corp.
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, precision cancer vaccines combined with companion diagnostic devices, reported...
Investigators Dose First Patient in Phase 1 Study of Treos Bio’s PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
14. Mai 2018 08:15 ET
|
Treos Bio Corp.
SAN FRANCISCO and LONDON, May 14, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
11. April 2018 08:15 ET
|
Treos Bio Corp.
SAN FRANCISCO and LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...